CC-292 + CC-223

CC-292 + CC-223 is an investigational oral combination regimen of two small molecule inhibitors: **CC-292** (also known as spebrutinib or AVL-292), a potent, selective, covalent Bruton tyrosine kinase (BTK) inhibitor, and **CC-223**, an ATP-competitive, selective inhibitor of the mammalian target of rapamycin (mTOR) kinase. Both molecules were developed for targeted therapy in hematologic malignancies such as relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. In clinical trial (CC-122-DLBCL-001, NCT02031419), this combination demonstrated enhanced toxicity and insufficient antitumor responses compared to some other regimens, leading to discontinuation of further development as a doublet in these settings[1][2][3][6].

Other names

spebrutinib + CC-223AVL-292 + CC-223